GIC Reinsurance

Arduous Road Ahead

Higher losses in agriculture and aviation led to increased 4QFY20 claims ratio of 89.1%, +1,917/-1,788bps YoY/QoQ. This resulted in underwriting losses of Rs 7.2bn. Investment income was hit by higher provisions of Rs 3.8bn bringing yield down to 7.7%. 4QFY20 APAT was Rs 12.2bn (+37.5% YoY).

- **NEP:** Led by healthy growth in property/health i.e., 71.7/17.5% YoY, 4QFY20 NEP grew 43.6% YoY to Rs 76.6bn. For FY20 the company delivered an NEP of Rs 443.5bn (+16.0% YoY).
- CORs: 4QFY20 CORs (cal.) increased 1,676bps YoY to 107.5% as ICR increased 1,917bps YoY to 89.1%. FY20 CORs (cal.) increased 929bps YoY to 114.5% as ICR increased 848bps YoY to 97.3%. This was mainly due to high losses in crop and fire.
- Crop's share in 4Q/FY20 NWP was 7.5/29.9% but its share in underwriting losses was higher at 377.1/56.5% as 1) losses due to unseasonal rainfall mainly in MH and MP leading to post harvest losses, and 2) loss development on crop portfolio for FY19. Management stated that crop losses should reduce FY21 onwards as the company had reduced its capacity to ~Rs 80bn (-40% YoY) and implemented stricter loss corridors.
- Investment book declined materially to Rs 702bn (-10.9/-12.4% YoY/QoQ) due to MTM hit on account of equity losses. 4QFY20 realized inv. yields (net of provisions) was at 7.7% (annualized). Investment yield (incl. FV change) declined to -20.3% (vs. 8.2% in FY19). On FV basis equity accounts for 35% of exposure. Duration of the fixed income book is ~7-10 yrs.
- GICRE provided Rs 3.8bn for doubtful debts and investment assets. Management highlighted that it has provided for 100% for secured as well as unsecured portion of ILFS (Rs 7.9bn) and DHFL (Rs 2.1bn). Exposure to ADAG was secured/unsecured at Rs 2.95/1.64bn. Co has provided for 15% secured and 100% unsecured portion.
- Management stated that it will book investment gains to shore up solvency, which is now at just 153! Solvency (incl. investment gains) stands strong at ~300%. Adj. for FV change (net of tax), GICRE's annualized ROE for FY20 works out to -28.8%.
- STANCE: GICRE is India's largest reinsurer but continues to make high underwriting losses (FY20 COR: 113.8%). A calibrated approach to underwriting is expected to change this over FY21-23E. While we are not fully convinced about the pathway to underwriting profitability, inexpensive valuations- FY22E P/ABV of 0.6x result in our BUY recommendation with a TP of Rs 185. We estimate an FY22E adj. RoE at 7.4%, and value GICRE at 0.7x FY22E ABV less 10% discount. We continue to rate GICRE a BUY with a TP of Rs 185 (Mar-22E P/ABV of 0.6x).

Einangial Cummany

| Financial Summar | y | | | | | | |
|------------------|--------|--------|---------|----------|----------|---------|---------|
| (Rs mn) | 4QFY20 | 4QFY19 | YoY(%) | 3QFY20 | QoQ(%) | FY21E | FY22E |
| Premium (NEP) | 76,644 | 53,359 | 43.6 | 79,816 | (4.0) | 438,560 | 458,491 |
| COR (%) | 107.5 | 90.7 | 1676bps | 129.2 | -2176bps | 103.2 | 102.1 |
| APAT | 12,218 | 8,889 | 37.5 | (10,355) | NM | 53,311 | 34,580 |
| Growth (%) | | | | | | NM | (35.1) |
| AEPS | 7.0 | 5.1 | 37.5 | (5.9) | NM | 30.4 | 19.7 |
| P/E (x) | | | | | | 5.1 | 7.9 |
| P/ABV (x) | | | | | | 0.6 | 0.6 |
| Adj. ROE (%) | | | | | | 23.1 | 11.2 |

Source: Company, HSIE Research

BUY

| CMP (as on 26) | CMP (as on 26 June 2020) | | |
|----------------|--------------------------|--------|--|
| Target Price | Rs 185 | | |
| NIFTY | 10,383 | | |
| | | | |
| KEY CHANGES | OLD | NEW | |
| Rating | BUY | BUY | |
| Price Target | Rs 180 | Rs 185 | |
| EDC 0/ | FY21E | FY22E | |
| EPS % | 77.8% | -9.6% | |

KEY STOCK DATA

| Bloomberg code | GICRE IN |
|-----------------------------|-----------|
| No. of Shares (mn) | 1,754 |
| MCap (Rs bn) / (\$ mn) | 272/3,596 |
| 6m avg traded value (Rs mn) | 67 |
| 52 Week high / low | Rs 334/82 |

STOCK PERFORMANCE (%)

| | 3M | 6M | 12M |
|--------------|------|--------|--------|
| Absolute (%) | 64.2 | (31.7) | (25.7) |
| Relative (%) | 46.7 | (17.1) | (14.5) |

SHAREHOLDING PATTERN (%)

| | Dec-19 | Mar-20 |
|-----------------|--------|--------|
| Promoters | 85.8 | 85.8 |
| FIs & Local MFs | 12.0 | 11.9 |
| FPIs | 0.3 | 0.3 |
| Public & Others | 2.0 | 2.1 |
| Pledged Shares | Nil | Nil |
| Source : BSE | | |

Madhukar Ladha, CFA madhukar.ladha@hdfcsec.com +91-22-6171-7323





INSTITUTIONAL RESEARCH

NEP growth at 43.6% YoY is largely ahead of our estimates (+27.4% vs estimates).

Claims ratio continue to remain elevated for third consecutive quarter.
Claims were higher owing to high losses in agriculture portfolio.

GICRE provided for Rs 1.5bn on account of provision for doubtful debts.

The company has provided 100% for ILFS and DHFL book.

GNPA/NNPA ratio was at 4.4/0.6% (+3/-21bps QoQ).

GICRE won a case in ITAT resulting in tax writeback of ~Rs 8.8bn.

Profit & Loss A/c

| Particulars (Rs mn) | 4QFY20 | 4QFY19 | YoY (%) | 3QFY20 | QoQ (%) |
|---|---------|--------|-----------|----------|-----------|
| Net premium written (NWP) | 84,400 | 59,078 | 42.9 | 98,091 | (14.0) |
| Net premiums earned (NEP) | 76,644 | 53,359 | 43.6 | 79,816 | (4.0) |
| Claims Incurred (net) | 68,319 | 37,333 | 83.0 | 85,416 | (20.0) |
| Commission (net) | 14,117 | 10,944 | 29.0 | 21,500 | (34.3) |
| Operating expenses | 1,497 | 1,315 | 13.8 | 462 | 223.9 |
| Premium deficiency | (130) | 4 | (3,123.3) | (164) | NM |
| Underwriting profit/(loss) | (7,159) | 3,762 | (290.3) | (27,399) | NM |
| Investment Income | 18,482 | 16,308 | 13.3 | 20,510 | (9.9) |
| Provisions (Other than taxation) | 2,336 | 1,687 | 38.5 | 82 | 2,759.6 |
| Provisions (for doubful debts) | 1,498 | 2,613 | (42.7) | 3,121 | (52.0) |
| Operating profits | 7,490 | 15,771 | (52.5) | (10,091) | NM |
| Other income | 3,742 | (570) | NM | 586 | 538.9 |
| PBT | 11,232 | 15,200 | (26.1) | (9,505) | NM |
| Tax | (490) | 5,961 | (108.2) | 339 | (244.8) |
| PAT | 11,722 | 9,240 | 26.9 | (9,844) | NM |
| Share of Profit in Associates Companies | 496 | (351) | NM | (512) | NM |
| APAT | 12,218 | 8,889 | 37.5 | (10,355) | NM |
| EO (Loss) / Profit (Net Of Tax) | 878 | - | NM | - | NM |
| RPAT | 13,096 | 8,889 | 47.3 | (10,355) | NM |
| | | | | | |
| Basic EPS | 7.5 | 5.1 | 47.3 | (5.9) | NM |
| | | | | | |
| Tax Rate (%) | (4.4) | 39.2 | -4358bps | (3.6) | -80bps |
| | | | | | |
| Ratios (%) | 4QFY20 | 4QFY19 | YoY (bps) | 3QFY20 | QoQ (bps) |
| Claims ratio | 89.1 | 70.0 | 1917bps | 107.0 | -1788bps |
| Commission ratio | 16.7 | 18.5 | -180bps | 21.9 | -519bps |
| Expenses ratio | 1.6 | 2.2 | -61bps | 0.3 | 132bps |
| Combined ratio | 107.5 | 90.7 | 1676bps | 129.2 | -2176bps |

Note: We include other expenses in operating expenses for calculation of opex $\overline{}$ ratio. Hence our opex and combined ratios will differ marginally from the company reported numbers.

APAT declined 109.9% YoY in FY20

Particulars (Rs mn) FY19 FY20 YoY (%) Net premium written (NWP) 393,909 467,654 18.7 Net premiums earned (NEP) 382,501 443,510 16.0 27.0 Claims Incurred (net) 339,696 431,504 Commission (net) 61,164 75,619 23.6 Operating expenses related to insurance business 3,463 4,735 36.7 Premium deficiency 53 194 267.1 **Underwriting profit/(loss)** -21,876 NM-68,541 Investment Income 64,478 71,469 10.8 Provisions (Other than taxation) 7,813 12,590 61.1 Operating profits 34,789 19,018 70.1 Other income 59.9 3,755 6,005 -3,657 **PBT** 38,543 (109.5)Tax 12,159 (100.0)4 PAT 26,385 -3,661 (113.9)Share of profit in associate companies 1,191 918 (22.9)**APAT** 27,576 -2,743 (109.9)EO (Loss) / Profit (Net Of Tax) NM 0 878 **RPAT** 27,576 -1,865 (106.8)**EPS** 15.7 (1.6)(109.4) Tax rate (%) 31.5 (0.1)-3,166bps Ratios (%) 88.8 Claims ratio 97.3 848bps 15.5 64bps Commission ratio 16.2 Expenses ratio 0.9 1.1 16bps 929bps Combined ratio 105.2 114.5

Management disclosed COR in domestic/foreign business at 112.7/118.5% for FY20. Management aims to bring down COR below 100%.

Note: We include other expenses in operating expenses for calculation of opex ratio. Hence our opex and combined ratios will differ marginally from the company reported numbers.

INSTITUTIONAL RESEARCH

Fire business grew at a healthy pace (+21.5% YoY) whereas agri saw a steep decline of 179.6% YoY.

Product mix

| NWP (Rs mn) | 4QFY19 | 1QFY20 | 2QFY20 | 3QFY20 | 4QFY20 | YoY (%) | QoQ (%) |
|-------------|---------|---------|--------|--------|--------|---------|---------|
| Agriculture | (7,995) | 102,651 | 11,557 | 19,235 | 6,361 | (179.6) | (66.9) |
| Fire | 20,617 | 27,029 | 27,033 | 23,704 | 25,053 | 21.5 | 5.7 |
| Motor | 20,836 | 23,818 | 26,566 | 23,073 | 21,247 | 2.0 | (7.9) |
| Health | 9,821 | 24,087 | 5,560 | 14,373 | 11,536 | 17.5 | (19.7) |
| Others | 15,799 | 19,404 | 17,458 | 17,707 | 20,203 | 27.9 | 14.1 |
| Total | 59,078 | 196,989 | 88,174 | 98,091 | 84,400 | 42.9 | (14.0) |

Source: Company, HSIE Research

| Share (%) | 4QFY19 | 1QFY20 | 2QFY20 | 3QFY20 | 4QFY20 | YoY (bps) | QoQ (bps) |
|-------------|--------|--------|--------|--------|--------|-----------|-----------|
| Agriculture | (13.5) | 52.1 | 13.1 | 19.6 | 7.5 | 2107bps | -1207bps |
| Fire | 34.9 | 13.7 | 30.7 | 24.2 | 29.7 | -521bps | 552bps |
| Motor | 35.3 | 12.1 | 30.1 | 23.5 | 25.2 | -1009bps | 165bps |
| Health | 16.6 | 12.2 | 6.3 | 14.7 | 13.7 | -295bps | -98bps |
| Others | 26.7 | 9.9 | 19.8 | 18.1 | 23.9 | -281bps | 589bps |
| Total | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | | |

Source: Company, HSIE Research

Share of motor in NWP has decreased materially in 4QFY20.

High underwriting losses for crop business was on account of 1) unseasonal rainfalls in FY20 and loss development of FY19.

lower claims and higher

Fire /agri. business grew at

 $(+25.0/22.4\%\ YoY)\ while$ health growth was moderate at 8.5% YoY.

a healthy pace

Lockdown resulted in profits for Motor segment. Underwriting and operating profits

| (Rs mn) | 4QFY19 | 1QFY20 | 2QFY20 | 3QFY20 | 4QFY20 | YoY (%) | QoQ (%) |
|----------------------|---------|---------|----------|----------|----------|-----------|---------|
| Underwriting profits | | | | | | | |
| Agriculture | (854) | (3,360) | (3,079) | (13,986) | (15,426) | NM | NM |
| Fire | (4,802) | 1,148 | (13,642) | (11,644) | 4,203 | NM | NM |
| Motor | 5,061 | (4,295) | 1,133 | (3,727) | 1,783 | (64.8) | (147.8) |
| Health | 94 | 677 | (5,078) | (694) | 892 | 848.5 | (228.4) |
| Others | 4,171 | (2,632) | (3,307) | 3,135 | 4,458 | 6.9 | 42.2 |
| Total | 3,671 | (8,462) | (23,972) | (26,916) | (4,091) | (211.5) | (84.8) |
| | | | | | | | |
| Operating profits | | | | | | | |
| Agriculture | 160 | (240) | 321 | (9,914) | (12,527) | (7,909.6) | NM |
| Fire | (1,424) | 3,692 | (9,807) | (7,449) | 7,979 | NM | NM |
| Motor | 8,529 | (1,837) | 4,478 | 287 | 5,649 | (33.8) | 1,869.1 |
| Health | 778 | 1,331 | (3,954) | 472 | 1,827 | 134.8 | 287.1 |
| Others | 6,530 | (658) | (247) | 5,849 | 7,276 | 11.4 | 24.4 |
| Total | 14,574 | 2,288 | (9,211) | (10,755) | 10,204 | (30.0) | NM |

Note: Operating profits for 4QFY20 are post -premium deficiency.

Source: Company, HSIE Research

Annual review: Product mix

| NWP (Rs mn) | FY19 | FY20 | YoY (%) |
|-------------|---------|---------|---------|
| Agriculture | 114,179 | 139,804 | 22.4 |
| Fire | 82,277 | 102,819 | 25.0 |
| Motor | 84,568 | 94,705 | 12.0 |
| Health | 51,196 | 55,556 | 8.5 |
| Others | 61,688 | 74,771 | 21.2 |
| Total | 393,908 | 467,654 | 18.7 |

Source: Company, HSIE Research

| Share (%) | FY19 | FY20 | YoY (bps) |
|-------------|-------|-------|-----------|
| Agriculture | 29.0 | 29.9 | 91bps |
| Fire | 20.9 | 22.0 | 110bps |
| Motor | 21.5 | 20.3 | -122bps |
| Health | 13.0 | 11.9 | -112bps |
| Others | 15.7 | 16.0 | 33bps |
| Total | 100.0 | 100.0 | |



Underwriting profits for motor/crop business declined ~12.4/11.9x YoY.

| Particulars (Rs mn) | FY19 | FY20 | YoY (%) |
|----------------------|----------|----------|-----------|
| Underwriting profits | | | |
| Agriculture | 3,280 | (35,851) | (1,193.1) |
| Fire | (21,659) | (19,936) | NM |
| Motor | 448 | (5,107) | (1,240.1) |
| Health | (2,791) | (4,203) | NM |
| Others | 1,888 | 1,654 | (12.4) |
| Total | (18,835) | (63,442) | NM |

| Particulars (Rs mn) | FY19 | FY20 | YoY (%) |
|---------------------|---------|----------|---------|
| Operating Profits | | | _ |
| Agriculture | 13,452 | (22,359) | (266.2) |
| Fire | (8,920) | (5,586) | NM |
| Motor | 12,067 | 8,577 | (28.9) |
| Health | 237 | (325) | (237.1) |
| Others | 10,750 | 11,895 | 10.7 |
| Total | 27,586 | (7,797) | (128.3) |

Note: Operating profits for FY20 are post -premium deficiency.

HDFC securities

As the solvency is just above the statutory limit, we expect NEP to moderate in 1QFY21.


Underwriting losses were

significant crop losses at

at ~Rs 7.2bn led by


~Rs 35.8bn.

NEP growth robust at 43.6% YoY



Source: Company, HSIE Research

Underwriting losses increased in 4QFY20




Source: Company, HSIE Research

We include other expenses (shareholders a/c) in calculation of underwriting profits.

Combined ratio increased +1,676bps YoY led by 1) increase in claims ratio (+1,917bps YoY), 2) decrease in commission / expense ratio (180/61bps YoY).

Combined ratios increased in 4QFY20



Source: Company, HSIE Research

We include other expenses for calculation of opex ratio.




Solvency ratio remained flattish sequentially at 153% and is marginally above the statutory requirement of 150%.

Investment book declined 10.9/12.4% YoY/QoQ on account of MTM losses resulting from steep fall in equity markets.


Investment leverage improved to ~1.83x (vs. 1.63x 3QFY20).

Solvency continues to remain weak




Source: Company, HSIE Research

Investment book declines



Source: Company, HSIE Research

Investment leverage improved in 4QFY20



Source: Company, HSIE Research We include FV reserve in net worth. Change in estimates

We have fine tuned our estimates to factor in higher premium growth and slightly lower COR's.

| Rs mn | | FY21E | | | FY22E | |
|----------------------|----------|----------|------------|----------|----------|------------|
| KS IIII | Old | New | Change (%) | Old | New | Change (%) |
| Net written premium | 442,785 | 459,225 | 3.7 | 460,496 | 477,595 | 3.7 |
| Net earned premium | 429,501 | 438,560 | 2.1 | 446,681 | 458,491 | 2.6 |
| COR (%) | 105.8 | 103.2 | -260bps | 104.2 | 102.1 | -208bps |
| COR (%) IRDAI | 105.8 | 103.2 | -260bps | 104.2 | 102.1 | -208bps |
| Underwriting profits | (27,198) | (17,517) | NM | (21,126) | (12,950) | NM |
| PAT | 29,986 | 53,311 | 77.8 | 38,261 | 34,580 | (9.6) |
| Investment book | 811,508 | 760,440 | (6.3) | 906,206 | 845,204 | (6.7) |
| ROE (%) | 8.2 | 23.1 | 1497bps | 9.3 | 11.2 | 191bps |

Source: Company, HSIE Research

Assumptions

| Assumptions | | | | | |
|--------------------------------|---------|---------|---------|---------|---------|
| (Rs mn) | FY19 | FY20P | FY21E | FY22E | FY23E |
| Net earned premium | 382,501 | 443,510 | 438,560 | 458,491 | 497,749 |
| Premium growth (%) | 0.1 | 16.0 | (1.1) | 4.5 | 8.6 |
| Ratios (%) | | | | | |
| Claims | 88.8 | 97.3 | 86.9 | 85.9 | 85.6 |
| Commission | 15.5 | 16.2 | 15.3 | 15.2 | 15.1 |
| Expenses | 0.8 | 0.3 | 1.0 | 1.0 | 1.0 |
| Combined | 105.1 | 113.8 | 103.2 | 102.1 | 101.8 |
| Segment wise premium (Rs mn) | | | | | |
| Fire | 83,726 | 97,510 | 115,062 | 124,267 | 130,480 |
| Marine | 12,336 | 16,884 | 18,234 | 19,693 | 20,875 |
| Motor | 84,244 | 89,816 | 93,408 | 107,420 | 120,310 |
| Health | 46,763 | 52,687 | 63,225 | 72,708 | 82,888 |
| Agriculture | 112,883 | 132,586 | 87,507 | 96,258 | 100,108 |
| Life | 4,860 | 8,548 | 9,574 | 10,531 | 11,373 |
| Others | 37,688 | 45,479 | 45,725 | 49,698 | 53,547 |
| Total | 382,501 | 443,510 | 432,735 | 480,574 | 519,581 |
| Product mix (%) | | | | | |
| Fire | 21.9 | 22.0 | 26.6 | 25.9 | 25.1 |
| Marine | 3.2 | 3.8 | 4.2 | 4.1 | 4.0 |
| Motor | 22.0 | 20.3 | 21.6 | 22.4 | 23.2 |
| Health | 12.2 | 11.9 | 14.6 | 15.1 | 16.0 |
| Agriculture | 29.5 | 29.9 | 20.2 | 20.0 | 19.3 |
| Life | 1.3 | 1.9 | 2.2 | 2.2 | 2.2 |
| Others | 9.9 | 10.3 | 10.6 | 10.3 | 10.3 |
| Total | 100 | 100 | 100 | 100 | 100 |
| Premium growth (%) | | | | | |
| Fire | 13.5 | 16.5 | 18.0 | 8.0 | 5.0 |
| Marine | 42.3 | 36.9 | 8.0 | 8.0 | 6.0 |
| Motor | (2.7) | 6.6 | 4.0 | 15.0 | 12.0 |
| Health | (20.0) | 12.7 | 20.0 | 15.0 | 14.0 |
| Agriculture | (4.5) | 17.5 | (34.0) | 10.0 | 4.0 |
| Life | 27.0 | 75.9 | 12.0 | 10.0 | 8.0 |
| Others | 16.0 | 20.7 | 6.0 | 8.0 | 7.0 |
| Total | 0.1 | 16.0 | (2.4) | 11.1 | 8.1 |
| Claims ratio (%) | | | | | |
| Fire | 100.2 | 92.0 | 85.0 | 82.0 | 80.0 |
| Marine | 66.7 | 77.0 | 75.0 | 72.0 | 71.0 |
| Motor | 85.0 | 90.0 | 83.0 | 85.0 | 86.0 |
| Health | 88.2 | 88.0 | 92.0 | 90.0 | 91.0 |
| Agriculture | 90.9 | 111.0 | 85.0 | 84.0 | 83.5 |
| Life | 122.2 | 102.0 | 101.0 | 100.0 | 99.0 |
| Others | 69.6 | 101.0 | 98.0 | 98.0 | 97.0 |
| Total | 88.8 | 97.3 | 86.9 | 85.9 | 85.6 |
| Source: Company, HSIE Research | | 27.00 | 33.5 | | |



Financials

Profit and Loss Account

| (Rs mn) | FY16 | FY17 | FY18 | FY19 | FY20P | FY21E | FY22E | FY23E |
|----------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|
| Net earned premiums | 153,382 | 263,747 | 382,000 | 382,501 | 443,510 | 438,560 | 458,491 | 497,749 |
| Growth (%) | 12.8% | 72.0% | 44.8% | 0.1% | 16.0% | -1.1% | 4.5% | 8.6% |
| Claims incurred | 129,683 | 215,293 | 330,582 | 339,696 | 431,504 | 381,097 | 393,939 | 426,196 |
| Commission (net) | 35,145 | 53,643 | 63,801 | 61,164 | 75,619 | 70,388 | 72,726 | 78,028 |
| Operating expenses | 1,827 | 5,300 | 3,948 | 4,534 | 4,929 | 4,592 | 4,776 | 5,158 |
| Foreign exchange (gain)/loss | (1,524) | 363 | 656 | (2,305) | (4,290) | - | - | - |
| Underwriting profit/(loss) | (11,749) | (10,852) | (16,987) | (20,589) | (64,251) | (17,517) | (12,950) | (11,634) |
| Investment Income | 41,479 | 45,871 | 54,031 | 64,477 | 71,469 | 83,648 | 59,164 | 71,742 |
| Provisions (Other than taxation) | 1,966 | 1,036 | 882 | 6,795 | 12,590 | 1,521 | 1,690 | 1,913 |
| Operating profit | 27,764 | 33,984 | 36,162 | 37,093 | (5,372) | 64,611 | 44,524 | 58,195 |
| Operating profit margin (%) | 18.1 | 12.9 | 9.5 | 9.7 | (1.2) | 14.7 | 9.7 | 11.7 |
| Interest expense | - | - | - | - | - | - | - | - |
| Other income | 2,426 | 181 | 134 | 1,450 | 1,715 | 858 | 429 | 214 |
| PBT | 30,191 | 34,165 | 36,296 | 38,543 | (3,657) | 65,468 | 44,953 | 58,409 |
| Tax | 3,318 | 4,123 | 4,349 | 12,159 | 4 | 13,094 | 11,328 | 14,719 |
| APAT | 28,211 | 31,406 | 31,456 | 27,576 | (2,743) | 53,311 | 34,580 | 44,665 |
| APAT Growth (%) | -1.9% | 11.3% | 0.2% | -12.3% | -109.9% | NM | -35.1% | 29.2% |
| RPAT | 28,211 | 31,406 | 31,456 | 27,576 | -1,865 | 53,311 | 34,580 | 44,665 |
| RPAT Growth (%) | -1.9% | 11.3% | 0.2% | -12.3% | -106.8% | NM | -35.1% | 29.2% |
| AEPS | 16.4 | 18.3 | 17.9 | 15.7 | (1.6) | 30.4 | 19.7 | 25.5 |
| EPS Growth (%) | -1.9% | 11.3% | -1.8% | -12.3% | -109.9% | NM | -35.1% | 29.2% |

Source: Company, HSIE Research

Balance Sheet

| (Rs mn) | FY16 | FY17 | FY18 | FY19 | FY20P | FY21E | FY22E | FY23E |
|----------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| SOURCES OF FUNDS | | | | | | | | |
| Share Capital | 4,300 | 4,300 | 4,386 | 8,772 | 8,772 | 8,772 | 8,772 | 8,772 |
| Reserves | 179,878 | 195,387 | 237,161 | 246,152 | 230,668 | 283,980 | 318,560 | 363,224 |
| Total Shareholders Funds | 184,178 | 199,687 | 241,547 | 254,924 | 239,440 | 292,752 | 327,332 | 371,996 |
| Fair Value Change Account | 234,567 | 300,372 | 298,343 | 304,240 | 148,721 | 200,157 | 224,242 | 251,268 |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Short-term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - |
| Net Deferred Tax Liability | (107) | (161) | (175) | (26) | (211) | - | - | - |
| TOTAL SOURCES OF FUNDS | 418,638 | 499,897 | 539,716 | 559,138 | 387,950 | 492,909 | 551,574 | 623,265 |
| | | | | | | | | |
| APPLICATION OF FUNDS | | | | | | | | |
| Net Block | 1,759 | 1,694 | 1,722 | 1,976 | 1,817 | 1,908 | 2,003 | 2,103 |
| Investments | 556,860 | 662,120 | 737,914 | 820,453 | 709,176 | 760,440 | 845,204 | 956,554 |
| Loans | 3,658 | 3,221 | 2,821 | 2,579 | 2,347 | 2,347 | 2,347 | 2,347 |
| Total Non-current Assets | | | | | | | | |
| Cash & Equivalents | 97,794 | 122,314 | 142,571 | 129,331 | 161,067 | 150,498 | 148,168 | 150,900 |
| Advances and Other assets | 100,851 | 181,284 | 239,639 | 267,722 | 331,194 | 347,273 | 354,005 | 374,094 |
| Total Current Assets | 198,644 | 303,598 | 382,211 | 397,053 | 492,261 | 497,772 | 502,173 | 524,994 |
| Current Liabilities | 250,721 | 338,092 | 460,542 | 521,114 | 643,313 | 581,994 | 593,133 | 637,294 |
| Provisions | 91,562 | 132,644 | 124,410 | 141,809 | 174,339 | 187,565 | 207,020 | 225,439 |
| Total Current Liabilities | 342,282 | 470,736 | 584,951 | 662,923 | 817,651 | 769,558 | 800,154 | 862,733 |
| Net Current Assets | (143,638) | (167,138) | (202,740) | (265,870) | (325,390) | (271,786) | (297,981) | (337,740) |
| TOTAL APPLICATION OF FUNDS | 418,638 | 499,897 | 539,716 | 559,138 | 387,950 | 492,909 | 551,574 | 623,265 |

GIC Reinsurance : Results Review 4QFY20




Key Ratios

| | FY16 | FY17 | FY18 | FY19 | FY20P | FY21E | FY22E | FY23E |
|------------------------------|-------|-------|-------|-------|--------|-------|-------|-------|
| PROFITABILITY (%) | | | | | | | | |
| Claims ratio | 84.5 | 81.6 | 86.5 | 88.8 | 97.3 | 86.9 | 85.9 | 85.6 |
| Commission ratio | 21.3 | 17.7 | 16.9 | 15.5 | 16.2 | 15.3 | 15.2 | 15.1 |
| Expenses ratio | 0.5 | 2.0 | 1.4 | 0.8 | 0.3 | 1.0 | 1.0 | 1.0 |
| Combined ratio | 106.4 | 101.4 | 104.9 | 105.1 | 113.8 | 103.2 | 102.1 | 101.8 |
| Underwriting profit | (7.7) | (4.1) | (4.4) | (5.4) | (14.5) | (4.0) | (2.8) | (2.3) |
| Investment yield | (1.3) | 18.2 | 7.3 | 8.2 | (12.6) | 17.8 | 9.8 | 10.3 |
| Investment Income /NEP | 25.8 | 17.0 | 13.9 | 15.1 | 13.3 | 18.7 | 12.5 | 14.0 |
| EBIT | 18.1 | 12.9 | 9.5 | 9.7 | (1.2) | 14.7 | 9.7 | 11.7 |
| PAT | 18.4 | 11.9 | 8.2 | 7.2 | (0.6) | 12.2 | 7.5 | 9.0 |
| ROE | 8.0 | 8.3 | 7.3 | 6.0 | (0.7) | 13.5 | 7.4 | 8.5 |
| Adjusted ROE | (1.3) | 20.4 | 7.0 | 6.9 | (28.8) | 23.1 | 11.2 | 12.3 |
| Core RoCE | 10.6 | 11.7 | 10.6 | 8.5 | (1.0) | 22.3 | 10.9 | 11.9 |
| RoCE | 8.0 | 8.3 | 7.3 | 6.0 | (0.7) | 13.5 | 7.4 | 8.5 |
| EFFICIENCY | | | | | | | | |
| Tax Rate (%) | 11.0 | 12.1 | 12.0 | 31.5 | (0.1) | 20.0 | 25.2 | 25.2 |
| Asset Turnover (x) | 0.4 | 0.6 | 0.7 | 0.7 | 0.9 | 1.0 | 0.9 | 0.8 |
| Claims os/NEP (x) | 1.4 | 1.1 | 1.1 | 1.2 | 1.3 | 1.2 | 1.2 | 1.1 |
| Technical reserves/NEP (x) | 1.9 | 1.6 | 1.4 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 |
| Investment leverage (x) | 1.6 | 1.7 | 1.7 | 1.8 | 1.7 | 1.9 | 1.8 | 1.8 |
| NWC (ex-cash) (days) | -575 | -401 | -330 | -377 | -401 | -351 | -355 | -358 |
| Debt/EBIT (x) | NA | NA | NA | NA | NA | NA | NA | NA |
| Net D/E | NA | NA | NA | NA | NA | NA | NA | NA |
| Interest Coverage | NA | NA | NA | NA | NA | NA | NA | NA |
| PER SHARE DATA | | | | | | | | |
| AEPS (Rs/sh) | 16.4 | 18.3 | 17.9 | 15.7 | (1.6) | 30.4 | 19.7 | 25.5 |
| DPS (Rs/sh) | 5.0 | - | 6.0 | 6.8 | 6.8 | - | 7.9 | 10.2 |
| BV (Rs/sh) | 202.5 | 238.3 | 256.7 | 266.7 | 199.2 | 251.3 | 281.2 | 318.0 |
| VALUATION | | | | | | | | |
| P/E | 9.5 | 8.5 | 8.7 | 9.9 | (99.4) | 5.1 | 7.9 | 6.1 |
| P/ABV | 0.77 | 0.65 | 0.61 | 0.58 | 0.78 | 0.62 | 0.55 | 0.49 |
| Dividend Yield (%) | 3.2 | 0.0 | 3.9 | 4.3 | 4.3 | 0.0 | 5.1 | 6.6 |



RECOMMENDATION HISTORY



| Date | CMP | Reco | Target |
|-----------|-----|------|--------|
| 1-Oct-19 | 228 | BUY | 250 |
| 14-Oct-19 | 211 | BUY | 250 |
| 13-Nov-19 | 271 | BUY | 250 |
| 9-Jan-20 | 245 | NEU | 256 |
| 12-Feb-20 | 238 | NEU | 264 |
| 2-Mar-20 | 164 | BUY | 270 |
| 12-Mar-20 | 152 | BUY | 270 |
| 11-Apr-20 | 117 | BUY | 180 |
| 29-Jun-20 | 155 | BUY | 185 |

From 2nd March 2020, we have moved to new rating system

Rating Criteria

BUY: >+15% return potential
ADD: +5% to +15% return potential
REDUCE: -10% to +5% return potential
SELL: > 10% Downside return potential



Disclosure:

I, Madhukar Ladha, CFA, MBA author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. **does not have** any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate **does not have** any material conflict of interest.

Any holding in stock -No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

HDFC securities

Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171-7330 www.hdfcsec.com